Scotiabank Maintains Sector Outperform on Castle Biosciences, Lowers Price Target to $33
Portfolio Pulse from jenniferd'souza@benzinga.com
Scotiabank analyst Sung Ji Nam maintains a Sector Outperform rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $54 to $33.
June 07, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Scotiabank maintains a Sector Outperform rating on Castle Biosciences but lowers the price target from $54 to $33.
The news directly mentions Castle Biosciences (CSTL) and the lowered price target by Scotiabank. While the lowered price target may have a negative impact on the stock, the maintained Sector Outperform rating suggests that the analyst still believes in the company's potential. This results in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100